Jasmin Fisher

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 94.5.237.16 (talk) at 21:26, 12 October 2022. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Jasmin Fisher
FRSB
Alma materWeizmann Institute of Science (PhD)
Scientific career
FieldsComputational modelling
Signalling networks
Cancer
Therapeutics[1]
InstitutionsWeizmann Institute of Science
École Polytechnique Fédérale de Lausanne
University of Cambridge
Microsoft Research
University College London
ThesisInsights into the mechanisms underlying T cell-mediated neuroprotection in injured central nervous system tissue (2003)
Doctoral advisorMichal Schwartz[2]
Websitewww.ucl.ac.uk/cancer/research/department-pathology/computational-cancer-biology Edit this at Wikidata

Jasmin Fisher FRSB is an Israeli-British biologist who is Professor of computational cancer biology at University College London. Her research investigates the development of software to study the molecular mechanisms that underpin the onset and progression of cancer.[1][3]

Early life and education

Fisher is from Israel.[2] She was an undergraduate student at the Ben-Gurion University of the Negev, where she studied biology and biophysics.[4] She was a doctoral researcher at the Weizmann Institute of Science, where she earned a PhD in neuroimmunology in 2003 supervised by Michal Schwartz.[2] Her doctoral research investigated the dialogue between the central nervous system and the immune system.[5][2]

Research and career

After her PhD, Fisher continued as a postdoctoral researcher in computer science where she worked with David Harel on the application of state charts to understand biological systems. She then moved to the École Polytechnique Fédérale de Lausanne as a postdoctoral researcher in computer science, where she worked with Thomas Henzinger on the development of novel formalisms and tools specifically tailored for modelling biological processes.[2] In 2007, Fisher was appointed as a principal researcher at Microsoft Research in Cambridge, and from 2013 held a joint position at the University of Cambridge.[6] Fisher develops software to model and understand the onset and progression of cancers and the mechanisms of drug resistance.[7] She considers the molecular processes that underpin cell-fate decisions in healthy and cancerous tissue.[6] To this end, she created Executable Biology,[8] which allows for the construction of computational models that can simulate biological mechanisms for detailed study.[9]

Working with AstraZeneca, Fisher's models enabled her to explore the processes behind abnormal blood production that can give rise to leukaemia.[10][8][11] This approach allows her to explore how to best target cancer drugs.[12] Fisher developed the BioModelAnalyzer tool: software which enables the creation and analysis biological network models.[12]

Fisher moved to University College London in 2019.[6]

Selected publications

Her publications[1][3] include:

  • Executable cell biology[8]
  • Decoding the regulatory network of early blood development from single-cell gene expression measurements[13]
  • Rethinking drug design in the artificial intelligence era[14]

Awards and honours

Fisher was elected a Fellow of the Royal Society of Biology (FRSB).[when?]

References

  1. ^ a b c Jasmin Fisher publications indexed by Google Scholar Edit this at Wikidata
  2. ^ a b c d e "Making Sense of a Complex Situation - Weizmann Wonder Wander - News, Features and Discoveries". weizmann.ac.il. Weizmann Wonder Wander - News, Features and Discoveries from the Weizmann Institute of Science. 2013-02-24. Retrieved 2022-08-05.
  3. ^ a b Jasmin Fisher publications from Europe PubMed Central
  4. ^ "Oncology 2014". thelancet.com. The Lancet. Retrieved 2022-08-05.
  5. ^ Fisher, Jasmine (2003). Insights into the mechanisms underlying T cell-mediated neuroprotection in injured central nervous system tissue. exlibrisgroup.com (PhD thesis). OCLC 884949838.
  6. ^ a b c UCL (2019-10-29). "Computational Cancer Biology". ucl.ac.uk. UCL Cancer Institute. Retrieved 2022-08-05.
  7. ^ "Computer Science for Fun - cs4fn: Executable Biology: Cell Biology". cs4fn.org. Retrieved 2022-08-05.
  8. ^ a b c Jasmin Fisher; Thomas A Henzinger (1 November 2007). "Executable cell biology". Nature Biotechnology. 25 (11): 1239–1249. doi:10.1038/NBT1356. ISSN 1087-0156. PMID 17989686. Wikidata Q36996114.
  9. ^ Jakob Ruess; Francesca Parise; Andreas Milias-Argeitis; Mustafa Khammash; John Lygeros (17 June 2015). "Iterative experiment design guides the characterization of a light-inducible gene expression circuit". Proceedings of the National Academy of Sciences of the United States of America. 112 (26): 8148–8153. Bibcode:2015PNAS..112.8148R. doi:10.1073/PNAS.1423947112. ISSN 0027-8424. PMC 4491780. PMID 26085136. Wikidata Q35818830.
  10. ^ "Cancer vs. the machine: how to personalise treatment using computing power". wired.co.uk. Wired. ISSN 1357-0978. Retrieved 2022-08-05.
  11. ^ Brackley, Paul (2017-11-29). "14 innovative women in Cambridge leading the way in healthcare". cambridgeindependent.co.uk. Cambridge Independent. Retrieved 2022-08-05.
  12. ^ a b "Microsoft and AstraZeneca cancer simulation to speed up advent of personalised medicines". businessweekly.co.uk. Retrieved 2022-08-05.
  13. ^ Victoria Moignard; Steven Woodhouse; Laleh Haghverdi; et al. (9 February 2015). "Decoding the regulatory network of early blood development from single-cell gene expression measurements". Nature Biotechnology. 33 (3): 269–276. doi:10.1038/NBT.3154. ISSN 1087-0156. PMC 4374163. PMID 25664528. Wikidata Q35218146.
  14. ^ Petra Schneider; W Patrick Walters; Alleyn T Plowright; et al. (4 December 2019). "Rethinking drug design in the artificial intelligence era". Nature Reviews Drug Discovery. doi:10.1038/S41573-019-0050-3. ISSN 1474-1776. PMID 31801986. Wikidata Q91698273.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Jasmin_Fisher&oldid=1115721215"